A Study of WVT078 in Patients With Multiple Myeloma (MM)

Phase 1 Terminated 56 enrolled Novartis Pharmaceuticals

Non-randomizedSequentialOpen-labelTreatment

Summary

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

Timeline

Start: 2019-12-05
Primary completion: 2024-12-02
Completion: 2024-12-02

Outcome

Outcome not reported

Stopped (Business): “The decision was made for business reasons and was not based on any safety or tolerability concerns”

Publications

Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, Wermke M, Souza AD, Kaufman JL, Cafro AM, Ocio EM, Doki N, Henson K, Trabucco G, Carrion A, Bender FC, Juif PE, Fessehatsion A, Fan L, Stonehouse JP, Blankenship JW, Granda B, De Vita S, Lu H. Preclinical discovery and initial clinical data of WVT078, a BCMA x CD3 bispecific antibody. Leukemia. 2023 Jun;37(6):1349-1360. doi: 10.1038/s41375-023-01883-3. Epub 2023 Apr 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	WHG626	Unknown	—	Oral
Subject	WVT078	Unknown	—	Intravenous